Registry for patients with pediatric atopic dermatitis receiving systemic treatments
Registry for Systemic Eczema Treatments
This study is creating a registry for kids with severe eczema who are using or planning to use systemic treatments to help researchers learn more about how well these treatments work and keep everyone updated on new options.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 400 (estimated) |
| Ages | 1 Year to 26 Years |
| Sex | All |
| Sponsor | Johns Hopkins University Academic / other |
| Locations | 1 site (Baltimore, Maryland) |
| Trial ID | NCT06136767 on ClinicalTrials.gov |
What this trial studies
The Registry for Systemic Eczema Therapies (RESET) is a comprehensive database and biospecimen repository aimed at patients with pediatric-onset atopic dermatitis (AD) who are using or planning to use systemic treatments. This registry will facilitate efficient recruitment for research studies and enable timely notifications about new FDA-approved therapies for AD. It will collect data to compare treatment effectiveness and monitor safety profiles of both traditional and novel systemic agents. Additionally, it aims to identify patients with moderate-to-severe AD who may benefit from emerging therapies.
Who should consider this trial
Good fit: Ideal candidates for this registry are individuals under 26 years old with a physician diagnosis of atopic dermatitis who have received care at Johns Hopkins since January 1, 2017.
Not a fit: Patients over 26 years old or those who have not received care at Johns Hopkins since January 1, 2017, may not benefit from this registry.
Why it matters
Potential benefit: If successful, this registry could enhance treatment options and outcomes for patients with atopic dermatitis by facilitating research and improving access to new therapies.
How similar studies have performed: Other registries and observational studies have shown success in improving patient outcomes and treatment understanding in similar conditions, making this approach promising.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria: * Age \<26 years old * Current physician diagnosis of atopic dermatitis * Provide signed informed consent if ≥ 18 years old * Provide signed informed consent by parent or legal guardian (if \<18 years old) and informed assent if applicable * Subject and/or parent/legal guardian is willing to be contacted in the future by study staff * Seen for clinical care at Johns Hopkins since 1/1/2017 * Previously on, currently on, or planning to initiate (within next 6 months) a systemic AD therapy Exclusion criteria: * Age ≥26 years old at the time of registry enrollment * Does not speak English * If \<18 years old, has a primary caretaker who does not speak English * If \<18 years old, parent/legal guardian is unwilling to sign the written informed consent * Is a foster child * Has not received clinical care at Johns Hopkins since 1/1/2017
Where this trial is running
Baltimore, Maryland
- Johns Hopkins University — Baltimore, Maryland, United States (Recruiting)
Study contacts
- Principal investigator: Joy Wan, MD MSCE — Johns Hopkins University
- Study coordinator: Zeena Mestari, BA
- Email: zmestar1@jh.edu
- Phone: 1 (848) 702-4101
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.